Case Study
Global Oncology Opportunity Assessment & Licensing Strategy Across 7 Indications
Quick Facts
7 Oncology Indications Evaluated
3 Major Global Regions Analyzed
2 Combination Therapies Assessed for Commercial Potential
Objective
Assess the commercial potential of two combination therapies for seven indications: 1L/2L Esophageal Squamous Cell Carcinoma (ESCC), 2L Head and Neck Squamous Cell Carcinoma (HNSCC), 2L Gastric Cancer, 2L Squamous Cell Non-Small Cell Lung Cancer (SC NSCLC), 1L Pancreatic Cancer, and 2L Triple-Negative Breast Cancer (TNBC).
Approach
- Commercial assessments were conducted across the US, EU4+UK, and Japan to inform client’s development strategy.
- Conduct secondary research to evaluate epidemiology, treatment guidelines, patient segmentation, and competitive landscape across key markets for each indication
- Assess pricing, coverage, and clinical pathways of relevant analog therapies to inform pricing and market access assumptions
- Forecast market share and revenue potential for each asset based on efficacy, launch timing, and payer dynamics
Results
Determined the potential commercial opportunity for the seven indications and delivered strategic recommendations to the client regarding the licensing opportunity.
